JP2021534168A5 - - Google Patents

Info

Publication number
JP2021534168A5
JP2021534168A5 JP2021507787A JP2021507787A JP2021534168A5 JP 2021534168 A5 JP2021534168 A5 JP 2021534168A5 JP 2021507787 A JP2021507787 A JP 2021507787A JP 2021507787 A JP2021507787 A JP 2021507787A JP 2021534168 A5 JP2021534168 A5 JP 2021534168A5
Authority
JP
Japan
Prior art keywords
cancer
independently selected
pharmaceutical composition
composition according
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021507787A
Other languages
English (en)
Japanese (ja)
Other versions
JP7364663B2 (ja
JP2021534168A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/046591 external-priority patent/WO2020037091A1/en
Publication of JP2021534168A publication Critical patent/JP2021534168A/ja
Publication of JP2021534168A5 publication Critical patent/JP2021534168A5/ja
Application granted granted Critical
Publication of JP7364663B2 publication Critical patent/JP7364663B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021507787A 2018-08-16 2019-08-15 イミダゾ[4,5-c]キノリン誘導体のNLRP3モジュレーター Active JP7364663B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862764834P 2018-08-16 2018-08-16
US62/764,834 2018-08-16
PCT/US2019/046591 WO2020037091A1 (en) 2018-08-16 2019-08-15 Imidazo[4,5-c]quinoline derived nlrp3-modulators

Publications (3)

Publication Number Publication Date
JP2021534168A JP2021534168A (ja) 2021-12-09
JP2021534168A5 true JP2021534168A5 (cg-RX-API-DMAC7.html) 2022-08-22
JP7364663B2 JP7364663B2 (ja) 2023-10-18

Family

ID=67777457

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021507787A Active JP7364663B2 (ja) 2018-08-16 2019-08-15 イミダゾ[4,5-c]キノリン誘導体のNLRP3モジュレーター

Country Status (7)

Country Link
US (1) US12201627B2 (cg-RX-API-DMAC7.html)
EP (1) EP3837014B1 (cg-RX-API-DMAC7.html)
JP (1) JP7364663B2 (cg-RX-API-DMAC7.html)
KR (1) KR102768379B1 (cg-RX-API-DMAC7.html)
CN (1) CN113038989A (cg-RX-API-DMAC7.html)
ES (1) ES2930171T3 (cg-RX-API-DMAC7.html)
WO (1) WO2020037091A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202101486RA (en) 2018-08-16 2021-03-30 Innate Tumor Immunity Inc Substitued 4-amino-1h-imidazo[4,5-c]quinoline compounds and improved methods for their preparation
WO2021142252A1 (en) * 2020-01-10 2021-07-15 Incyte Corporation Tricyclic compounds as inhibitors of kras
WO2021150613A1 (en) 2020-01-20 2021-07-29 Incyte Corporation Spiro compounds as inhibitors of kras
CN121270550A (zh) * 2020-04-16 2026-01-06 因赛特公司 稠合三环kras抑制剂
WO2021231526A1 (en) 2020-05-13 2021-11-18 Incyte Corporation Fused pyrimidine compounds as kras inhibitors
WO2022047093A1 (en) 2020-08-28 2022-03-03 Incyte Corporation Vinyl imidazole compounds as inhibitors of kras
WO2022072783A1 (en) 2020-10-02 2022-04-07 Incyte Corporation Bicyclic dione compounds as inhibitors of kras
WO2022204112A1 (en) 2021-03-22 2022-09-29 Incyte Corporation Imidazole and triazole kras inhibitors
CN115124524A (zh) * 2021-03-26 2022-09-30 浙江海正药业股份有限公司 三环类衍生物及其制备方法和用途
WO2023283213A1 (en) 2021-07-07 2023-01-12 Incyte Corporation Tricyclic compounds as inhibitors of kras
CA3224841A1 (en) 2021-07-14 2023-01-19 Zhenwu Li Tricyclic compounds as inhibitors of kras
CA3229855A1 (en) 2021-08-31 2023-03-09 Incyte Corporation Naphthyridine compounds as inhibitors of kras
US12030883B2 (en) 2021-09-21 2024-07-09 Incyte Corporation Hetero-tricyclic compounds as inhibitors of KRAS
US12030884B2 (en) 2021-10-01 2024-07-09 Incyte Corporation Pyrazoloquinoline KRAS inhibitors
KR20240101561A (ko) 2021-10-14 2024-07-02 인사이트 코포레이션 Kras의 저해제로서의 퀴놀린 화합물

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2706547T3 (es) 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US9175082B2 (en) 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
RS61400B1 (sr) 2013-05-02 2021-02-26 Anaptysbio Inc Antitela usmerena protiv programirane smrti-1 (pd-1)
CU24377B1 (es) 2013-05-18 2018-12-05 Aduro Biotech Inc Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting
CA3175360C (en) 2013-05-31 2024-05-28 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
CR20160319A (es) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
US10654807B2 (en) 2013-12-20 2020-05-19 The University Of Kansas Toll-like receptor 8 agonists
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
CN112546230A (zh) 2014-07-09 2021-03-26 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
CN112546238A (zh) 2014-09-01 2021-03-26 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
MA42971A (fr) 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
DK3303394T3 (da) 2015-05-29 2020-07-06 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
JP6869987B2 (ja) 2015-09-01 2021-05-12 アジェナス インコーポレイテッド 抗pd−1抗体及びその使用方法
CN108289912A (zh) 2015-09-01 2018-07-17 先天肿瘤免疫公司 具有提高的免疫力或免疫抑制性细胞因子抗性的免疫细胞及其用途
EP3402255B1 (en) 2016-02-02 2021-03-31 Huawei Technologies Co., Ltd. Emission power verification method, user equipment, and base station
WO2017132827A1 (en) 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
WO2017184735A1 (en) 2016-04-19 2017-10-26 Ifm Therapeutics, Inc Nlrp3 modulators
EP3445761A1 (en) 2016-04-19 2019-02-27 Innate Tumor Immunity, Inc. Nlrp3 modulators
TWI674261B (zh) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑

Similar Documents

Publication Publication Date Title
JP2021534158A5 (cg-RX-API-DMAC7.html)
JP2021522249A5 (cg-RX-API-DMAC7.html)
JP2020125349A5 (cg-RX-API-DMAC7.html)
ES2728739T3 (es) Derivado de rapamicina para el tratamiento de un tumor sólido asociado con angiogénesis desregulada
JP2023515235A5 (cg-RX-API-DMAC7.html)
JP2020508302A5 (cg-RX-API-DMAC7.html)
JP2025065346A5 (ja) 組み合わせ物
NZ580009A (en) Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
JP2019535746A5 (cg-RX-API-DMAC7.html)
JP2018510191A5 (cg-RX-API-DMAC7.html)
JP2020517616A5 (cg-RX-API-DMAC7.html)
RU2016108667A (ru) Комбинированная терапия для лечения рака
JP2022517109A5 (cg-RX-API-DMAC7.html)
JP2019535744A5 (cg-RX-API-DMAC7.html)
JP2018062523A5 (cg-RX-API-DMAC7.html)
JP2022031403A5 (cg-RX-API-DMAC7.html)
RU2010128107A (ru) Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp
JP2023506787A5 (cg-RX-API-DMAC7.html)
JP2024511996A5 (cg-RX-API-DMAC7.html)
JP2015536986A5 (cg-RX-API-DMAC7.html)
JP2020527139A5 (cg-RX-API-DMAC7.html)
RU2014154009A (ru) Комбинация ингибитора 17-альфа-гидроксилазы (с17,20-лиазы) и специфического ингибитора pi-3k для лечения онкологического заболевания
RU2013134359A (ru) Комбинированная терапия с применением индуктора и ингибитора аутофагии для лечения новообразований
RU2020113749A (ru) Аналоги таиланстатина
JP2022517110A5 (cg-RX-API-DMAC7.html)